Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
‘Our Focus Is On Driving Long-Term EBITDA Growth,’ Endo Insists
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.
